Skip to main content
Kexing Biopharm logo

Kexing Biopharm — Investor Relations & Filings

Ticker · 688136 ISIN · CNE100006ZG6 LEI · 529900Z34Q1M9A907771 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 754 across all filing types
Latest filing 2023-07-25 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688136

About Kexing Biopharm

https://www.kexingbiopharm.com/

Kexing Biopharm is an innovative biopharmaceutical enterprise engaged in the research, development, production, and sales of recombinant protein drugs and micro-ecological preparations. The company focuses on developing treatments for therapeutic areas including kidney diseases, oncology, antiviral therapy, autoimmune disorders, metabolic diseases, and degenerative diseases. A key product in its portfolio is Erythropoietin Injection. Kexing Biopharm maintains a comprehensive quality system that aligns with international standards, covering the entire drug lifecycle from production and quality control to release and transportation, ensuring the continuous and stable manufacturing of safe and effective medicines.

Recent filings

Filing Released Lang Actions
关于本次募集资金投向属于科技创新领域的说明
Capital/Financing Update Classification · 95% confidence The document is a detailed explanation from 科兴生物制药股份有限公司 regarding the use of funds raised from a specific stock issuance in 2023. It discusses the company's business, the investment projects funded by the raised capital, including clinical research and industrialization projects, and the necessity and feasibility of these projects. The document references compliance with the "上市公司证券发行注册管理办法" (Securities Issuance Registration Measures for Listed Companies) and focuses on the allocation and use of raised funds, which is characteristic of a capital/financing update. There is no indication that this is a full annual or interim report, audit report, or earnings release. The document is not a brief announcement but a substantive explanation of fundraising use, fitting the Capital/Financing Update category (CAP). The document length (9108 characters) supports it being a full explanation rather than a short announcement or certification.
2023-07-25 Chinese
北京市嘉源律师事务所关于科兴生物制药股份有限公司实际控制人免于以要约方式增持股份的专项核查意见
Regulatory Filings Classification · 95% confidence The document is a legal opinion issued by a law firm regarding a specific shareholding increase by the actual controller and chairman of the company, Mr. Deng Xueqin. It discusses the legality and compliance of the share increase with relevant laws and regulations, including the exemption from a mandatory tender offer under the "Acquisition Management Measures". The document includes detailed information about the shareholding changes, the legal qualifications of the shareholder, and the disclosure obligations fulfilled by the company. It is not a financial report, earnings release, or management discussion, but rather a legal verification and compliance opinion related to a capital increase event. This fits the category of a Regulatory Filing (RNS) as it is a regulatory compliance document and does not constitute a full financial report or announcement of a report publication. The document length is sufficient and contains substantive content, not just a brief announcement or certification letter, but it is primarily a legal opinion on a capital increase event, which is best classified under Regulatory Filings (RNS).
2023-07-25 Chinese
关于公司监事辞职及补选非职工代表监事的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the resignation of a company supervisor and the election of a new non-employee representative supervisor. It includes details about the resignation, the legal basis for the change, and the election of a new supervisor pending shareholder approval. There are no financial statements, earnings data, or detailed financial analysis present. The content focuses on changes in the company's supervisory board, which falls under management or board information. Therefore, the document fits the category of Board/Management Information (MANG). The document length is short and it is not a report publication announcement or a certification. Hence, the classification is MANG with high confidence.
2023-06-30 Chinese
关于使用部分募集资金向全资子公司提供无息借款以实施募投项目的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement by 科兴生物制药股份有限公司 regarding the use of part of its raised funds to provide an interest-free loan to its wholly-owned subsidiary for implementing a fundraising investment project. It details the board and supervisory meetings approving the loan, the background of the fundraising, the use of funds, and includes independent directors' and supervisory opinions. The document is regulatory in nature, focused on the use of raised capital and internal approvals, without containing financial statements or quarterly/yearly financial results. It is not a full annual or interim report, earnings release, or audit report. It is also not a proxy, voting result, or management change announcement. The document is a formal regulatory announcement about capital use and internal approvals, fitting best under Regulatory Filings (RNS). The document length is about 5,220 characters, which is sufficient for a detailed announcement but does not contain financial statements or detailed financial analysis. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2023-06-30 Chinese
独立董事关于第二届董事会第七次会议相关议案的意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion regarding a specific board meeting agenda item about the use of raised funds for an interest-free loan to a wholly-owned subsidiary. It references the company's articles of association and legal compliance but does not contain financial statements or detailed financial data. The document is short (744 characters) and focuses on governance and board-level approval rather than financial reporting. This fits the category of Board/Management Information (MANG), which covers announcements of board decisions or management opinions related to company governance and operations.
2023-06-30 Chinese
第二届监事会第七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the company's Supervisory Board meeting, including approval of using funds for a loan to a subsidiary and election of a new non-employee representative supervisor. It includes voting results and references related announcements on the stock exchange website. The content focuses on board/management decisions and meeting outcomes rather than financial results or reports. It is not an annual or interim report, earnings release, or audit report. It is not a proxy solicitation or voting results declaration for a shareholder meeting, but a supervisory board meeting resolution announcement. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is a formal announcement of board decisions, not a full report or presentation.
2023-06-30 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.